Skip to main content
. 2020 Sep 8;8:565020. doi: 10.3389/fcell.2020.565020

FIGURE 6.

FIGURE 6

Prickle2 treatment ameliorates AD-like pathology through Wnt/PCP pathway. (A) Western blotting analysis of protein levels of JNK, p-JNK (T183/Y185), c-Jun, and p-c-Jun (S63) in brain tissues from WT, 3 × TG and 3 × TG/Prickle2 treatment mice (n = 6 per group). (B) Quantification of the protein levels of p-JNK (T183/Y185) and p-c-Jun (S63) by densitometric analyses (n = 6 per group). (C) Prickle2 mRNA (n = 3 per group) in N2a/APP695sw cells transfected with empty vector pcDNA3 (Vec), pcDNA3-Prickle2, pSilencer 2.1-U6 neo (shR-NC), and pSilencer-Prickle2 (shR-Prickle2). (D) Western blotting analysis of protein levels of Prickle2, JNK, p-JNK (T183/Y185), c-Jun, p-c-Jun (S63), Tau, p-Tau S202 and p-Tau S396 in N2a/APP695sw cells transfected with indicated plasmids or siRNAs. (E–I) Quantification of the protein levels of Prickle2, p-JNK (T183/Y185), p-c-Jun (S63) p-Tau S202 and p-Tau S396 by densitometric analyses (n = 3 per group). (B,C,E–I) ANOVA followed by Bonferroni’s post hoc test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.